HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T Cell and IFNγ Cross-Resistance

Researchers investigated evolution of HLA class II-loss tumors that escaped cytotoxic CD4 T cell activity and contributed to immunotherapy resistance.